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Cardiovascular presentation of acute coronary syndrome 
(ACS) patients with severe acute respiratory disease coro-
navirus-2 (SARS-CoV-2), referred to as “COVID-19”, can be 
complex with varying presentations of ST-elevation myocardial 
infarction (STEMI), stress cardiomyopathy, non-ischaemic 
cardiomyopathy, coronary spasm or non-specific myocardial 
injury.(1,2) Concern has been expressed worldwide regarding 
the failure of patients with emergent ACS to access health-
care during the SARS-coronavirus disease 19 (COVID-19) 
pandemic, which was declared to be a pandemic by the World 
Health Organization (WHO) on 14 March 2020. The first 
COVID-19 case was diagnosed in South Africa on 5 March 
2020. On 15 March 2020, the South African President, Cyril 
Ramaphosa, declared a national state of disaster in terms of 
the Disaster Management Act, 2002, and coronavirus alert level 
5 lockdown regulations were applied to reduce the transmis-
sion of the virus from 27 March. Alert level 4 lockdown 
regulations were then made applicable from 1 May 2020. A 
marked decrease in the volume of patients presenting with 
ACS was observed during lockdown in April 2020 by one of 
the three major private hospital groups in South Africa. 
We conducted a study of admission rates of ACS in all 
Mediclinic hospitals in South Africa. The aim of the study was to 
quantify the extent of change in admission rates of ACS 
subtypes and to establish the degree of change in subtype 
proportions in the private sector assumed to be related to 
COVID-19 and/or lockdown implementation. Time intervals 
were demarcated by lockdown measures (March: pre-lockdown 
versus April: post-lockdown implementation), and compari-
sons were performed with equitable time periods (2019 versus 
2020). For the comparison of proportions, data for April and 
May were summated.
CHANGE IN ACS SUB-TYPE 
HOSPITALISATION RATES
ICD-10 codes (WHO ICD-10; Version 19) at discharge were 
used to examine trend in ACS subtypes. 
 ■ I20.0 Unstable angina 
 ■ I21.0 Acute transmural myocardial infarction of anterior wall 
 ■ I21.1 Acute transmural myocardial infarction of inferior wall
 ■ I21.2 Acute transmural myocardial infarction of other sites
 ■ I21.3 Acute transmural myocardial infarction of 
unspecified site
 ■ I21.4 Acute subendocardial myocardial infarction
 ■ I21.9 Acute myocardial infarction, unspecified
The number of patients hospitalised for ACS for a given month 
is reported in Table 1. Change is expressed as the difference 
between 2019 and 2020 number of hospitalised patients/2019 
number of hospitalised patients. A slight decline in hospitalisa-
tion rates in March 2020 compared with March 2019 is evident 
for ACS, mirrored by a similar degree of change in unstable 
angina (UA) hospitalisations, while non ST- elevation myocardial 
infarction (NSTEMI) increased slightly, with reciprocal changes 
in myocardial infarctions, unspecified (MIU), and no change in 
STEMI hospitalisations. Following the application of full lock-
down regulations, the largest degree of change in ACS hospi-
talisations is observed for UA. The 43% reduction in ACS is 
further explained by negative changes in order of magnitude in 
MIU, NSTEMI and STEMI hospitalisations. 
Our findings corroborate findings of other countries regarding 
the decline in numbers of acute myocardial infarction hospi-
talisations – albeit across differing but equitable time periods 
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and also employing differing definitions of ACS subtypes(1-4) – 
but clearly to a lesser extent. In addition, greater reductions 
were observed in NSTEMI compared with STEMI hospitalisa-
tions in our investigation, as was observed elsewhere,(3,4) and 
again to a lesser extent, for instance compared with a report of 
a 65.4% reduction in NSTEMI admissions and a 26.5% reduc-
tion in STEMI admissions in Italy during the pandemic.(4) 
CHANGE IN STEMI AND NSTEMI 
PROPORTIONS OF ACS PRESENTATION 
SINCE THE START OF THE PANDEMIC 
As collated internationally for 2006 - 2012(5) and cited in a 
recent editorial,(6) STEMI presentation comprised 25% - 40% 
of myocardial infarction presentations. Proportions for STEMI 
and NSTEMI were reported as 41% and 32% of ACS admis-
sions in South Africa for the time period 2007 - 2008.(7) Upon 
analysis of the data for the time periods 1 March 2020 - 
30 April 2019 (n=2513 patients) and 1 March 2020 - 30 April 
2020 (n=1593 patients), we observed much lower propor-
tions of ACS for STEMI and NSTEMI than those reported 
approximately 10 years ago for South Africa.(7) During lock-
down, the proportion of ACS patients with a discharge diag-
nosis of STEMI and NSTEMI increased slightly between the 
equivalent months (5.5% - 6.8% and 11.7% - 14.8%, respec-
tively), whereas the proportion of UA patients decreased from 
66.7% - 62.2%. The proportion of the remainder of the ACS 
patients who had a discharge diagnosis of MIU did not appear 
to change (16.2% and 16.1% respectively) between the 2 time 
periods. The change in proportions of ACS presentations 
between 2019 and 2020 for both STEMI and NSTEMI – with 
2019 proportions as denominator – amounted to a relative 
increase in respective admissions of 24.3% and 27.2%. Thus, 
proportions of ACS subtypes changed considerably during 
lockdown in South Africa. This may be of clinical relevance and 
may inform strategies to optimise the management of ACS 
during the pandemic.
We acknowledge that this a crude estimate of the impact of 
the pandemic on ACS admissions, with no consideration for 
mechanisms leading to the reduction in hospitalisation for 
acute myocardial infarctions. Although the ACS rates are still 
relatively low, the expectation is that the rates and proportion 
of STEMI and NSTEMI presentations will most likely increase in 
the near future, considering COVID-related economic, myo-
cardial and mental health challenges, as well as other pos-
sible hypotheses for changes in ACS volume during the 
COVID-19 pandemic, which were elegantly expounded in a 
recent editorial.(6) 
We would like to recommend an increased alertness for 
masked ACS based on a sound grasp of the pathophysiology of 
COVID-19 infections, an urgency for a systems approach to 
preparedness for the management of all subtypes of ACS, and 
intensified and extended follow-up and rehabilitation of COVID 
ACS patients.
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TABLE I: Change in acute coronary syndrome case presentations during corresponding months in 2019 and 2020 in private South 
African hospitals.
March April
Condition ICD-10 code 2019 (n) 2020 (n) Change % 2019 (n) 2020 (n) Change %
ACS 1 254 1 165 -7.1 1 269 718 -43.4
STEMI I21.0 - I21.2 73 73 0.0 65 55 -15.4
NSTEMI I21.4 138 163 18.1 156 116 -25.6
UA I20.0 831 758 -8.8 852 414 -51.4
MIU I21.3 212 171 -19.3 196 133 -32.1
STEMI = ST-elevation myocardial infarction, NSTEMI = Non ST-elevation myocardial infarction, UA = Unstable angina, MIU = Unspecified myocardial infarction.
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